Michael J Pishvaian

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. pmc A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 70:843-53. 2012
  2. pmc A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer 118:5403-13. 2012
  3. pmc A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 71:627-33. 2013
  4. pmc Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2113, USA
    Clin Cancer Res 16:4038-45. 2010
  5. pmc Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
    Marie K Gurka
    Department of Radiation Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:44. 2013
  6. pmc The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway
    M Carla Cabrera
    Department of Oncology, Georgetown University, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 5:810-21. 2012

Detail Information

Publications6

  1. pmc A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 70:843-53. 2012
    ..We conducted a Phase I study of imatinib in combination with paclitaxel in patients with advanced or metastatic solid tumors...
  2. pmc A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies
    Michael J Pishvaian
    Lombardi Comprehensive Cancer Center, Developmental Therapeutics Program, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer 118:5403-13. 2012
    ..The authors conducted a phase 1 study to determine the recommended phase 2 dose, safety, tolerability, and pharmacokinetics of efatutazone...
  3. pmc A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA
    Cancer Chemother Pharmacol 71:627-33. 2013
    ....
  4. pmc Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2113, USA
    Clin Cancer Res 16:4038-45. 2010
    ..The two studies, GX001 and GX005, evaluated the safety and tolerability of weekly 1-hour and 3-hour infusions of obatoclax, respectively...
  5. pmc Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety
    Marie K Gurka
    Department of Radiation Oncology, Georgetown University Hospital, Washington, DC 20007, USA
    Radiat Oncol 8:44. 2013
    ..This Pilot study assessed the safety of concurrent full-dose gemcitabine with SBRT for LAPC...
  6. pmc The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway
    M Carla Cabrera
    Department of Oncology, Georgetown University, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 5:810-21. 2012
    ..In summary, the study distinguished CDK4 and phosphorylated pRb as targets for chemoprevention regimens targeting reversal of hyperplasia and dysplasia...